UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver ...

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...